2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 492

Calprotectin Levels Correlate with Inflammation in Early Rheumatoid Arthritis before Disease-Modifying Antirheumatic Drug Treatment and after 12 Months of Treatment
Abstract Number: 493

The 2010 ACR/EULAR Criteria Are Not Sufficiently Accurate in the Early Identification of Autoantibody-Negative Rheumatoid Arthritis
Abstract Number: 494

Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Abstract Number: 495

The Relative Performance of 28-Joint Disease Activity Score Based on C-Reactive Protein with Three Versus Four Components in Patients with Rheumatoid Arthritis
Abstract Number: 496

Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes
Abstract Number: 497

The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis
Abstract Number: 498

Higher Serum Heavy Metals Concentrations Are Associated with Rheumatoid Arthritis : A Study of the Korean National Health and Nutrition Examination Survey (KNHANES)
Abstract Number: 499

High Levels of Mir-451a Differentiate Patients at Risk of Developing RA from Healthy Controls
Abstract Number: 500

Can Thiol/Disulphide Is a Novel Marker in Rheumatoid Arthritis?
Abstract Number: 501

Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis
Abstract Number: 502

Use, Usability and Feasibility of a Mapp for Patients with Rheumatoid Arthritis – First Results
Abstract Number: 503

Anti-CCP Titer and Prevalence Is Influenced By Age at Rheumatoid Arthritis Onset- Analysis Based on a Nationwide Database in Japan
Abstract Number: 504

Clinical Significance of Multiple Autoantibody Specificities in Rheumatoid Arthritis: The Role of Anti-Citrullinated Alpha-Enolase and Anti-Interferon Inducible Protein 16 Antibodies
Abstract Number: 505

The Longitudinal Stability of the RA Biomarkers RF and ACPA in Classifying RA Subtypes over Extended Follow up
Abstract Number: 506

The Relationship Between Elevations in CRP with Physical Function and Radiographic Progression over the Long-Term in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].